Triple

T184503
Position Surface form Disambiguated ID Type / Status
Subject European Medicines Agency E3950 entity
Predicate hasCommittee P1396 FINISHED
Object Committee for Orphan Medicinal Products
The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
E24718 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Committee for Orphan Medicinal Products | Statement: [European Medicines Agency, hasCommittee, Committee for Orphan Medicinal Products]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Committee for Orphan Medicinal Products
Context triple: [European Medicines Agency, hasCommittee, Committee for Orphan Medicinal Products]
  • A. Committee for Proprietary Medicinal Products
    The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
  • B. European Medicines Agency
    The European Medicines Agency is the European Union’s regulatory authority responsible for the scientific evaluation, supervision, and safety monitoring of medicines for human and veterinary use.
  • C. Committee for Advanced Therapies
    The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
  • D. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
    The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is a global body that develops and promotes unified scientific and technical standards to ensure the safety, quality, and efficacy of medicines worldwide.
  • E. Committee for Medicinal Products for Veterinary Use
    The Committee for Medicinal Products for Veterinary Use is the European Medicines Agency’s scientific committee responsible for evaluating and providing opinions on veterinary medicines in the European Union.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Committee for Orphan Medicinal Products
Triple: [European Medicines Agency, hasCommittee, Committee for Orphan Medicinal Products]
Generated description
The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: Committee for Orphan Medicinal Products
Target entity description: The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
  • A. Committee for Proprietary Medicinal Products
    The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
  • B. European Medicines Agency
    The European Medicines Agency is the European Union’s regulatory authority responsible for the scientific evaluation, supervision, and safety monitoring of medicines for human and veterinary use.
  • C. Committee for Advanced Therapies
    The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
  • D. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
    The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is a global body that develops and promotes unified scientific and technical standards to ensure the safety, quality, and efficacy of medicines worldwide.
  • E. Committee for Medicinal Products for Veterinary Use
    The Committee for Medicinal Products for Veterinary Use is the European Medicines Agency’s scientific committee responsible for evaluating and providing opinions on veterinary medicines in the European Union.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a25497e2f08190a040f8c6e1842643 completed Feb. 28, 2026, 2:36 a.m.
NER Named-entity recognition batch_69a25926be9c8190a4cfce66f57589d1 completed Feb. 28, 2026, 2:55 a.m.
NED1 Entity disambiguation (via context triple) batch_69a31159301481909a3521339d2338fa completed Feb. 28, 2026, 4:01 p.m.
NEDg Description generation batch_69a3138da9888190848b490ccb5ddf15 completed Feb. 28, 2026, 4:10 p.m.
NED2 Entity disambiguation (via description) batch_69a313f9e0f881909e2b03bcd5f19876 completed Feb. 28, 2026, 4:12 p.m.
Created at: Feb. 28, 2026, 2:40 a.m.